ERBB2 and infantile convulsions and choreoathetosis: As iCCA is increasingly recognized as a group of molecularly defined subtypes rather than a single disease entity, a key future question is whether neoadjuvant treatment could also incorporate targeted or immunotherapeutic agents in biomarker-selected populations, such as FGFR2-directed therapy for FGFR2-fusion-positive tumors or HER2-directed treatment for ERBB2-amplified disease.